Skip to main content
Daniel Landsburg, MD, Oncology, Philadelphia, PA

DanielJLandsburgMD

Oncology • Philadelphia, PA

Physician

Join to view full profile

Dr. Landsburg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Landsburg's full profile

Already have an account?

  • Office

    3400 Civic Center Blvd
    2nd Floor, West Pavilion
    Philadelphia, PA 19104
    Phone+1 215-662-2867

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2014
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2008 - 2011
  • Lewis Katz School of Medicine at Temple University
    Lewis Katz School of Medicine at Temple UniversityClass of 2008

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2008 - 2024
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas into Effective New Therapies  
    Daniel J Landsburg, Brad S Kahl, Clinical Lymphoma, Myeloma, & Leukemia
  • Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
    Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

  • Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
    Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
    Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
    Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • A Community Hospital Is a Destination for Advanced Cancer Care
    A Community Hospital Is a Destination for Advanced Cancer CareOctober 5th, 2023
  • Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma
    Retrospective Analysis Identifies Need for Better Classification of Rare LymphomaDecember 4th, 2019
  • CAR T Studies Highlight Abramson Cancer Center Research at ASH Annual Meeting
    CAR T Studies Highlight Abramson Cancer Center Research at ASH Annual MeetingNovember 26th, 2018
  • Join now to see all

Dr. Daniel Landsburg, Dr. Daniel Landsburg, MD, Dr. D Landsburg, Dr. Daniel J Landsburg